Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Selected Balance Sheet Data

v3.20.1
Note 3 - Selected Balance Sheet Data
9 Months Ended
Mar. 31, 2020
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

Note 3. Selected Balance Sheet Data:

 

Inventories:

 

Inventories consist of (in thousands):

 

   

March 31,

   

June 30,

 
   

2020

   

2019

 

Raw materials

  $ 47,263     $ 40,913  

Finished goods(1)

    56,059       53,376  

Inventories, net

  $ 103,322     $ 94,289  

 

(1) Finished goods inventory of $3,649 and $3,239 is included within other long-term assets in the respective March 31, 2020 and June 30, 2019, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

   

March 31,

   

June 30,

 
   

2020

   

2019

 

Land

  $ 7,561     $ 7,065  

Buildings and improvements

    182,300       175,019  

Machinery and equipment

    141,506       124,233  

Property and equipment, cost

    331,367       306,317  

Accumulated depreciation

    (166,355

)

    (152,278

)

Property and equipment, net

  $ 165,012     $ 154,039  

 

Intangible Assets:

 

Intangible assets consist of (in thousands):

 

   

March 31,

   

June 30,

 
   

2020

   

2019

 

Developed technology

  $ 434,367     $ 435,679  

Trade names

    146,428       147,296  

Customer relationships

    209,651       214,320  

Patents

    2,377       2,133  

Intangible assets

    792,823       799,428  

Accumulated amortization

    (262,490

)

    (219,999

)

Intangible assets, net

  $ 530,333     $ 579,429  

 

Changes to the carrying amount of net intangible assets for the nine months ended March 31, 2020 consist of (in thousands):

 

Beginning balance

  $
579,429
 

Acquisitions

    -  

Other additions

    214  

Amortization expense

    (45,625

)

Currency translation

    (3,685 )

Ending balance

  $ 530,333  

 

The estimated future amortization expense for intangible assets as of March 31, 2020 is as follows (in thousands):

 

2020 remainder

  $ 15,423  

2021

    59,545  

2022

    57,335  

2023

    55,469  

2024

    53,008  

Thereafter

    289.553  

Total

  $ 530,333  

 

Goodwill:

 

Changes to the carrying amount of goodwill for the nine months ended March 31, 2020 consist of (in thousands):

 

   

Protein Sciences

   

Diagnostics and

Genomics

   

Total

 

Beginning balance

  $ 377,407       355,260     $ 732,667  

Acquisitions (Note 4)

    -       -       -  
Prior year acquisitions/adjustments (Note 4)     (326 )     -       (326 )

Currency translation

    (6,424 )     (86

)

   
(6,510
)

Ending balance

  $ 370,657     $ 355,174     $ 725,831  

 

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2019. No indicators of impairment were identified as part of our assessment. 

 

No triggering events were identified during the nine months ended March 31, 2020. There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.